Reference entry · Dual-modified ACTH fragment analog
N-Acetyl Semax Amidate
Also known as: Ac-Semax-NH2 · N-acetyl Semax with C-terminal amidation
- Class
- Dual-modified ACTH fragment analog
- Size
- 7 amino acids (N-acetyl, C-terminal amide)
- Primary targets (literature)
- Semax-related neurotrophin research context
- Regulatory context
- Not FDA-approved. Dual-modified sequences require explicit MS fragmentation or accurate-mass confirmation — not inferable from Semax COAs.
Overview
N-acetyl Semax amidate combines N-terminal acetylation with C-terminal amidation on the Semax heptapeptide backbone. Both modifications are common medicinal-chemistry strategies for peptide stability — the result is a chemically distinct research material from Semax and Adamax.
Mechanism in research literature
Literature on this exact dual-modified sequence is sparse relative to parent Semax; mechanistic framing typically references parent ACTH-fragment analog biology with PK/stability hypotheses for terminal modifications.
Common research focus areas
- Terminal modification chemistry (acetyl + amide)
- Identity verification vs. Semax and Adamax
- Peptide stability in lyophilized storage
- Orthogonal MS confirmation of both modifications
Full literature roundup
Read the cited research summary
A dual-modified Semax derivative with N-terminal acetylation and C-terminal amidation. Stability chemistry, identity verification, and literature context.
N-Acetyl Semax Amidate research roundup · 6 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.